hVIVO, a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, has announced that its German subsidiary, CRS, has signed contracts worth more than £5m since September.
The early-phase clinical trial service contracts have been signed with five clients, including two returning mid-sized German pharma customers, reaffirming CRS's strong reputation and long-standing relationships in Germany.
These pharma partnerships, given their volume and consistency, strengthen the Group's sales pipeline and orderbook for 2026 and beyond.
The clinical trials are due to commence this year and H1 2026, with the majority of revenue recognised in 2026.
They will take place at the Mannheim and Kiel sites, studying drug candidates targeting multiple therapeutic areas, including cardiometabolic, dermatology, infectious disease, renal impairment and cancer.
CRS has strong expertise across this range of therapeutic areas, expanding the Group's addressable market.
Venn Life Sciences will be supporting these contracts with its Biometry service, demonstrating the cross-selling benefits being realised from the integration of CRS into the Group.
CRS have conducted more than 1800 clinical trials and provides advice to its clients across every aspect of their study, from feasibility and study design to trial management, recruitment, execution and close-out.
These studies span Phase I and Phase II in healthy volunteers and patients, supported by CRS's participant recruitment platform, recently enhanced by hVIVO's Volunteer Management System, improving efficiency in recruitment for CRS trials.
Dr Yamin 'Mo' Khan, CEO of hVIVO, said: "Securing more than £5 million in new contracts, including two mid-sized pharma clients, underscores our strong reputation and the strategic importance of CRS within the Group."
"These wins demonstrate the success of our integration strategy and the value we deliver through combined expertise across the hVIVO Group."
"CRS has seen an increased conversion rate of proposals to contracts year-to-date versus 2024 and with a robust sales pipeline and continued efficiency improvements, CRS remains on track to become earnings accretive in 2026."
Professor Thomas Forst, Chief Medical Officer of hVIVO, said: "At CRS, we are committed to delivering high-quality clinical trial services that accelerate the development of safe and effective medicines for patients worldwide."
"These new studies span multiple therapeutic areas and showcase the depth of our expertise and the trust our clients place in us."
"By combining scientific excellence with operational efficiency, we continue to strengthen our position as a leading partner for early-phase clinical research."